Author: Hsu, Shih-Hsien; Yeh, Ming-Lun; Wang, Shen-Nien
Title: New Insights in Recurrent HCV Infection after Liver Transplantation Document date: 2013_4_23
ID: 0hbeso65_30
Snippet: The current therapy against HCV infection, consisting of a combination of pegylated interferon (IFN) and ribavirin (RBV), is limited by resistance, adverse effects, and high costs. The absence of preventive regiment is a major limitation for patients undergoing LT for HCV-related liver failure. Moreover, accelerated progression to liver cirrhosis after graft reinfection and limited efficacy of IFN-based therapies for recurrent HCV are two major c.....
Document: The current therapy against HCV infection, consisting of a combination of pegylated interferon (IFN) and ribavirin (RBV), is limited by resistance, adverse effects, and high costs. The absence of preventive regiment is a major limitation for patients undergoing LT for HCV-related liver failure. Moreover, accelerated progression to liver cirrhosis after graft reinfection and limited efficacy of IFN-based therapies for recurrent HCV are two major clinical issues leading to poor posttransplant outcome of the HCV recipients [80] . Thus, novel preventive and therapeutic antivirals are urgently needed. Viral entry is required for initiation, spread, and maintenance of infection. HCV entry is a multistep process orchestrated by a number of viral and host cell factors.
Search related documents:
Co phrase search for related documents- adverse effect and HCV infection: 1
- adverse effect and limited efficacy: 1, 2
- adverse effect and liver cirrhosis: 1, 2
- adverse effect and liver failure: 1, 2
- adverse effect and therapeutic preventive: 1, 2
- adverse effect and viral entry: 1, 2
- cell factor and current therapy: 1
- cell factor and HCV infection: 1
- cell factor and host viral cell factor: 1, 2, 3, 4, 5, 6
- cell factor and limited efficacy: 1, 2, 3
- cell factor and liver failure: 1, 2, 3
- cell factor and therapeutic preventive: 1, 2, 3, 4
- cell factor and urgently need: 1
- cell factor and viral entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- clinical issue and HCV infection: 1, 2
- current therapy and graft reinfection: 1
- current therapy and HCV entry: 1, 2, 3, 4, 5
- current therapy and HCV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- current therapy and HCV infection current therapy: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date